MONTREAL--(BUSINESS WIRE)--Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced that Gaétan Gravel, Life Sciences Portfolio Director at the Fonds de solidarité FTQ, and Joseph (Joe) Zakrzewski have been appointed to the company’s Board of Directors. Mr. Gravel and Mr. Zakrzewski join existing directors Jonathan Wener, Chairman & CEO, Canderel; Dr. Jens Eckstein, President, SR One (corporate venture capital arm of GlaxoSmithKline); Jean George, General Partner, Advanced Technology Ventures; Daniel Hetu, Managing Partner, Lumira Capital; and Richard Andrews, President and CEO, Thrasos Therapeutics.
Help employers find you! Check out all the jobs and post your resume.
